These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16021205)

  • 21. Emerging pharmacological therapies for the irritable bowel syndrome.
    Maneerattanaporn M; Chang L; Chey WD
    Gastroenterol Clin North Am; 2011 Mar; 40(1):223-43. PubMed ID: 21333909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Irritable bowel treatment].
    Fassov J; Fynne L; Krarup AL
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
    Lacy BE
    Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of Kolofort for the treatment of patients with irritable bowel syndrome].
    Tsukanov VV; Rzhavicheva OS; Vasjutin AV; Dunaevskaja OV; Tonkih JL; Bronnikova EP
    Ter Arkh; 2016; 88(8):40-45. PubMed ID: 27636926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review.
    Camilleri M
    JAMA; 2021 Mar; 325(9):865-877. PubMed ID: 33651094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug treatment options for irritable bowel syndrome: managing for success.
    Dunphy RC; Verne GN
    Drugs Aging; 2001; 18(3):201-11. PubMed ID: 11302287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based position statement on the management of irritable bowel syndrome in North America.
    American College of Gastroenterology Functional Gastrointestinal Disorders Task Froce
    Am J Gastroenterol; 2002 Nov; 97(11 Suppl):S1-5. PubMed ID: 12425585
    [No Abstract]   [Full Text] [Related]  

  • 29. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
    Cremonini F; Talley NJ
    Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
    Basseri RJ; Kunkel D; Low K; Conklin JL; Pimentel M
    J Clin Gastroenterol; 2011 Oct; 45(9):790-3. PubMed ID: 21301356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the management of irritable bowel syndrome.
    Cash BD; Chey WD
    Curr Gastroenterol Rep; 2003 Dec; 5(6):468-75. PubMed ID: 14602054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
    Schoenfeld P
    Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irritable bowel syndrome: a clinical review.
    Chey WD; Kurlander J; Eswaran S
    JAMA; 2015 Mar; 313(9):949-58. PubMed ID: 25734736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA.
    Tuteja AK; Talley NJ; Gelman SS; Alder SC; Thompson C; Tolman K; Hale DC
    Dig Dis Sci; 2008 Jan; 53(1):271-6. PubMed ID: 17549631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacological treatment of the irritable bowel syndrome: a technical review].
    Remes-Troche JM; Gómez-Escudero O; Nogueira-de Rojas JR; Carmona-Sánchez R; Pérez-Manauta J; López-Colombo A; Sanjurjo-García JL; Noble-Lugo A; Chávez-Barrera JA; González-Martínez M
    Rev Gastroenterol Mex; 2010; 75(1):42-66. PubMed ID: 20423782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations.
    Lacy BE; Moreau JC
    J Am Assoc Nurse Pract; 2016 Jul; 28(7):393-404. PubMed ID: 27436200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irritable bowel syndrome: update on pathogenesis and management.
    Alaradi O; Barkin JS
    Med Princ Pract; 2002; 11(1):2-17. PubMed ID: 12116690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.